miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
about
miR-155 as a Biomarker in B-Cell MalignanciesRole of microRNAs in chemoresistanceMicroRNAs in B-cells: from normal differentiation to treatment of malignanciesPutting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemiaRoles of microRNA-146a and microRNA-181b in regulating the secretion of tumor necrosis factor-α and interleukin-1β in silicon dioxide-induced NR8383 rat macrophagesBenzene-Induced Aberrant miRNA Expression Profile in Hematopoietic Progenitor Cells in C57BL/6 MiceMiR-181a contributes to bufalin-induced apoptosis in PC-3 prostate cancer cells.Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells.Targeted regulation of MiR-98 on E2F1 increases chemosensitivity of leukemia cells K562/A02.MiR-181b sensitizes glioma cells to teniposide by targeting MDM2.Tumor surveillance by circulating microRNAs: a hypothesis.MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.Clinical implications of microRNAs in cancer.Identification of a set of miRNAs differentially expressed in transiently TIA-depleted HeLa cells by genome-wide profiling.Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia.Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysisRole of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.miR-638 regulates differentiation and proliferation in leukemic cells by targeting cyclin-dependent kinase 2Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication.miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progressionIL-4 Up-Regulates MiR-21 and the MiRNAs Hosted in the CLCN5 Gene in Chronic Lymphocytic Leukemia.Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interactionmiR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.MiR-181a influences the cognitive function of epileptic rats induced by pentylenetetrazol.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesComparison of non-coding RNAs in human and canine cancerEwing's Sarcoma: An Analysis of miRNA Expression Profiles and Target Genes in Paraffin-Embedded Primary Tumor Tissue.Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF.miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review).Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
P2860
Q26746573-6CC260A6-E1E1-4910-BA52-A284C6649692Q26770485-7C65303C-E0EA-4677-8B17-8D2463008BDFQ26824682-50527E51-2F36-472D-963B-75D0719AB904Q28085240-9DF02F44-9276-4FAB-8573-4C56609458FFQ28241703-89BE4B79-5ED8-4029-99F9-8ED69D167400Q28389474-887476A9-8ECF-4EDF-B50B-335C6E02BF31Q28394910-3B813C2B-6047-465A-8CBA-9D9E39902BA2Q31144343-EB0B5058-C3D9-4FFE-916A-70662CACEE7EQ33364071-E24CF454-DFE6-462F-95CE-5A0072DFF6BCQ33690671-EE632311-CED4-4907-B604-639428DE1F09Q33879017-6A77F32C-DC48-4482-ADD4-4E265C417974Q34136136-41FE0E9E-B523-410B-A78E-F99DB2118E80Q34324228-BB84EAD7-BE0B-45BF-B800-96CC2BC005D3Q34545956-A329CEC0-4CEB-4473-94BE-C961B475996BQ34570698-1D18D4F7-77F1-4096-AE8A-D610E4676386Q34578702-B25F5490-4BB8-43DB-B05E-36BE6EFF1C30Q34599349-EE43896F-DE2D-4893-9509-B98BB3F54384Q34637868-935BEED8-8A44-45BB-9A7C-D835AF5EC2FDQ34769735-39414C25-D04B-4A56-ADCA-9FA983CF8823Q35000253-1BEFD2E4-A55E-445C-B7E9-EFCF2847D4C9Q35121352-74EBF177-89A1-462E-B52D-44FFDCA33EE4Q35125641-9AAB7D32-A386-4852-B15B-BDFC84468697Q35176071-21971E89-82C6-4B1E-9806-184080F63CD4Q35238507-F7CC11E4-6F81-41CB-B1AA-986A712ECB68Q35562364-729E9E3C-0380-4C31-88D7-DAB30D1F049DQ35613623-43C48584-5C99-4A84-B4A9-4B3797B57E90Q35679203-5CFAA606-E8FD-4B5D-8E16-1D96B3ADEFFDQ35681504-DAB39448-EBE6-4C8A-B5A4-B71A440743FDQ35791145-D500C5C9-D11C-4457-A1B5-64B9D861AD1BQ35958274-07FB8675-6F9B-43DC-A30D-C571DDA1ABB5Q36020966-DB75D8CB-28EF-4B9D-ADD9-EE2B08E751D2Q36256357-6B240843-1440-47B2-883B-0698B7FD0696Q36375245-2400FFB3-FCB9-42AD-B276-B4ED6623842DQ36602853-F7BBEC16-9C32-4AF6-B2C5-166550470ACDQ36746944-8A8637BF-512E-41AF-8678-C82808970048Q36939163-0A9F0F8F-0226-4A92-AC5E-5D2BA9CDA81AQ37327584-35704B5D-A7FC-4861-AB94-E991A382F49DQ37565608-7CDA5387-98DA-4588-8B22-3A02ADB3EBA2Q37644854-BA0E12D4-F93B-4892-9E73-EC6B76FB36DAQ37706078-1DD7B398-C4EF-474E-A610-18DE5D21D016
P2860
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@ast
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@en
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@nl
type
label
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@ast
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@en
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@nl
prefLabel
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@ast
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@en
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@nl
P2093
P356
P1433
P1476
miR-181a/b significantly enhan ...... multiple anti-apoptosis genes.
@en
P2093
Cheng Fang
Dan-Xia Zhu
Jian-Yong Li
Kou-Rong Miao
P304
P356
10.1093/CARCIN/BGS179
P407
P577
2012-05-18T00:00:00Z